NCT00492947撤回1 期
0608 GCC:Phase I Study of Intra-tumoral Injection of Dendritic Cells for the Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
适应症
试验速览
- 阶段
- 1 期
- 状态
- 撤回
- 试验地点
- 2
- 主要终点
- safety
研究概览
简要总结
This research study is testing a new treatment of cancer of the head and neck.
Purpose
This research study is being done to:
- Test the safety of the experimental cancer vaccine made of dendritic cells. An experimental vaccine is one that is not approved by the Food and Drug Administration (FDA).
- To learn what effects (good and bad) the vaccine will have on you and your head and neck cancer.
- To learn if the vaccine will stimulate your body's white blood cells, which are part of your immune system (your body's natural defense system).
详细描述
White blood cells are part of the body's defense system. Sometimes when you have cancer, your body does not know that the cancer cells are making you sick. We hope to teach your white blood cells to find and destroy your cancer cells with a vaccine. The vaccine will be made from a special kind of blood cell called a dendritic cell. This is the cell that will carry the information about your cancer to your white blood cells in your body.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Squamous cell carcinoma of the head and neck in patients with unresectable recurrent disease or distant metastasis or patients who fail conventional radiation therapy and/or chemotherapy and refuse surgical salvage.
- •Presence of cervical metastasis that is able to be accessed for injection
- •Biopsy accessible tumor (metastatic or primary)
- •>18 years of age.
- •The following laboratory values obtained ≤14 days prior to registration:
- •ANC ≥1500
- •PLT ≥100,000
- •Hgb ≥ 9.0 g/dL
- •Alkaline phosphatase ≤3 x UNL
- •AST ≤3 x UNL
- •Creatinine ≤1.5 x UNL
- •Life expectancy ≥6 months.
- •ECOG performance status 0, 1, or
- •No chemotherapy for prior 4 weeks.
排除标准
- •Pregnant women.
- •Nursing women.
- •Men or women of childbearing potential who are unwilling to employ adequate contraception (condoms, diaphragm, birth control pills, injections, intrauterine device {IUD}, abstinence.)
- •Known HIV infection.
- •Concurrent use of systemic immunosuppressants.
- •Other immunocompromising condition that in the opinion of the physician renders the patient a poor candidate for this trial.
- •Other active cancer requiring therapy to control the disease.
- •Unwillingness to return for follow-up evaluations over a period of up to 2 years following completion of protocol therapy.
- •Other intercurrent medical problems that, in the opinion of the investigator, would make participation in the study hazardous for the patient
- •Patients in whom the otolaryngologist, radiation oncologist, and medical oncologist can not agree on a consensus node to treat.
- •Patients with CNS metastasis or involvement of sites where an inflammatory response would constitute an immediately life threatening situation.
结局指标
主要结局
safety
时间窗: 5 years
Efficacy as measured by RECIST criteria
时间窗: 5 years
次要结局
- Characterize the immune response to the vaccine(2 years)
研究者
研究点 (2)
Loading locations...
相似试验
招募中
2 期
Intratumoral Administration of Daromun in Non-melanoma Skin Cancer PatientsCarcinoma, Basal CellCarcinoma, Cutaneous Squamous CellNCT04362722Philogen S.p.A.40
招募中
1 期
Intratumoral Injection of Autologous CD1c (BDCA-1)+ MyDC, Avelumab, and Ipilimumab Plus Systemic NivolumabSolid TumorMetastases to Soft TissueNCT03707808Universitair Ziekenhuis Brussel18
已完成
1 期
Vaccine Therapy in Treating Patients With Malignant Peripheral Nerve Sheath Tumor That is Recurrent or Cannot Be Removed by SurgeryMetastatic Malignant Peripheral Nerve Sheath TumorNeurofibromatosis Type 1Recurrent Malignant Peripheral Nerve Sheath TumorNCT02700230Mayo Clinic30
已完成
1 期
CPG 7909 + Local Radiotherapy in Recurrent Low-Grade LymphomasNon-Hodgkin LymphomaMycosis FungoidesNCT00185965Ronald Levy30
已完成
1 期
Evaluate The Toxicity And Feasibility Of Intra-Tumoral InjectionNeoplasm MetastasesNCT00668382University of Massachusetts, Worcester11